JP7305543B2 - 組織特異的Ｗｎｔシグナル増強分子およびその使用 - Google Patents

組織特異的Ｗｎｔシグナル増強分子およびその使用 Download PDF

Info

Publication number
JP7305543B2
JP7305543B2 JP2019541341A JP2019541341A JP7305543B2 JP 7305543 B2 JP7305543 B2 JP 7305543B2 JP 2019541341 A JP2019541341 A JP 2019541341A JP 2019541341 A JP2019541341 A JP 2019541341A JP 7305543 B2 JP7305543 B2 JP 7305543B2
Authority
JP
Japan
Prior art keywords
tissue
polypeptide
molecule
domain
wnt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019541341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506701A (ja
JP2020506701A5 (cg-RX-API-DMAC7.html
Inventor
ゼンジャン ジャン，
ジェニファー ジーン ブレイディ，
アーロン ケン サト，
ウェン－チェン イェー，
ヤン リー，
鉄平 山口
Original Assignee
スロゼン オペレーティング， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スロゼン オペレーティング， インコーポレイテッド filed Critical スロゼン オペレーティング， インコーポレイテッド
Publication of JP2020506701A publication Critical patent/JP2020506701A/ja
Publication of JP2020506701A5 publication Critical patent/JP2020506701A5/ja
Priority to JP2023057334A priority Critical patent/JP7635291B2/ja
Application granted granted Critical
Publication of JP7305543B2 publication Critical patent/JP7305543B2/ja
Priority to JP2024195763A priority patent/JP2025020347A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
JP2019541341A 2017-01-26 2018-01-26 組織特異的Ｗｎｔシグナル増強分子およびその使用 Active JP7305543B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023057334A JP7635291B2 (ja) 2017-01-26 2023-03-31 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP2024195763A JP2025020347A (ja) 2017-01-26 2024-11-08 組織特異的Ｗｎｔシグナル増強分子およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762450804P 2017-01-26 2017-01-26
US62/450,804 2017-01-26
US201762487135P 2017-04-19 2017-04-19
US62/487,135 2017-04-19
PCT/US2018/015595 WO2018140821A1 (en) 2017-01-26 2018-01-26 Tissue-specific wnt signal enhancing molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023057334A Division JP7635291B2 (ja) 2017-01-26 2023-03-31 組織特異的Ｗｎｔシグナル増強分子およびその使用

Publications (3)

Publication Number Publication Date
JP2020506701A JP2020506701A (ja) 2020-03-05
JP2020506701A5 JP2020506701A5 (cg-RX-API-DMAC7.html) 2021-02-25
JP7305543B2 true JP7305543B2 (ja) 2023-07-10

Family

ID=62978866

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019541341A Active JP7305543B2 (ja) 2017-01-26 2018-01-26 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP2023057334A Active JP7635291B2 (ja) 2017-01-26 2023-03-31 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP2024195763A Pending JP2025020347A (ja) 2017-01-26 2024-11-08 組織特異的Ｗｎｔシグナル増強分子およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023057334A Active JP7635291B2 (ja) 2017-01-26 2023-03-31 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP2024195763A Pending JP2025020347A (ja) 2017-01-26 2024-11-08 組織特異的Ｗｎｔシグナル増強分子およびその使用

Country Status (7)

Country Link
US (2) US11958891B2 (cg-RX-API-DMAC7.html)
EP (1) EP3574019A4 (cg-RX-API-DMAC7.html)
JP (3) JP7305543B2 (cg-RX-API-DMAC7.html)
CN (1) CN110234662A (cg-RX-API-DMAC7.html)
AU (1) AU2018211985B2 (cg-RX-API-DMAC7.html)
CA (1) CA3050133A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018140821A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
AU2018211985B2 (en) 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
EP3731867A4 (en) 2017-12-19 2022-04-06 Surrozen Operating, Inc. Anti-lrp5/6 antibodies and methods of use
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
US12006368B2 (en) 2017-12-19 2024-06-11 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
CN112654363A (zh) 2018-07-09 2021-04-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
EP3886905A4 (en) * 2018-12-27 2022-08-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. BISPECIFIC ANTIBODY FOR MEMBRANE CLEARANCE OF TARGET RECEPTORS
EP3924381A4 (en) * 2019-02-11 2023-07-26 Surrozen Operating, Inc. MODULATION OF WNT SIGNALING IN EYE DISEASES
US20220175884A1 (en) * 2019-04-02 2022-06-09 Surrozen Operating, Inc. Modulation of wnt signaling in auditory disorders
KR20220024460A (ko) * 2019-06-11 2022-03-03 안틀라 테라퓨틱스 아이엔씨. 다가 fzd 및 wnt 결합 분자 및 이의 용도
WO2020257758A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
KR102192471B1 (ko) * 2019-10-18 2020-12-17 주식회사 인코스팜 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물
WO2021142410A1 (en) * 2020-01-09 2021-07-15 Retinal Solutions, LLC Neural regeneration with synthetic protein administration
CN115427446A (zh) * 2020-02-24 2022-12-02 瑟罗泽恩奥普瑞汀公司 Wnt超级激动剂
EP4244256A4 (en) * 2020-11-10 2024-12-25 The Scripps Research Institute ANTIBODIES FOR OPIOID TREATMENTS
KR20230109668A (ko) 2020-11-16 2023-07-20 서로젠 오퍼레이팅, 인크. 간-특이적 Wnt 신호 증강 분자 및 그의 용도
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
CN113307882B (zh) * 2021-05-12 2022-12-20 东北大学 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物
CN113293214A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因wnt2扩增的引物探针及其应用
KR20240040088A (ko) * 2021-07-15 2024-03-27 디오젠엑스 R-스폰딘 단백질의 재조합 변이체 및 그의 용도
JPWO2023080159A1 (cg-RX-API-DMAC7.html) * 2021-11-02 2023-05-11
CN116789843B (zh) * 2022-03-16 2024-09-17 伯桢生物科技(杭州)有限公司 Wnt重组蛋白及其应用
CN116836274B (zh) * 2022-03-23 2024-11-22 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
CA3258980A1 (en) * 2022-06-21 2023-12-28 Surrozen Operating, Inc. WNT SIGNALING MODULATION IN CORNEAL DISORDERS
WO2025146152A1 (zh) * 2024-01-04 2025-07-10 上海宝济药业股份有限公司 一种药物组合物及其应用
CN120647751B (zh) * 2025-08-18 2025-12-02 成都迈科康生物科技有限公司 抗人乳头瘤病毒e1蛋白的抗体或其试剂盒和相关应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008093646A1 (ja) 2007-02-01 2008-08-07 National University Corporation NARA Institute of Science and Technology Wntシグナル伝達系活性化ペプチド
JP2014530816A (ja) 2011-10-14 2014-11-20 ノバルティスアーゲー Ｗｎｔ経路関連疾患のための抗体および方法
JP2015511484A (ja) 2012-02-28 2015-04-20 ノバルティス アーゲー ＲＮＦ４３変異ステータスを利用したＷｎｔシグナル伝達阻害剤の投与のためのがん患者選択法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
ES2345256T3 (es) * 2003-10-10 2010-09-20 Deutsches Krebsforschungszentrum Composiciones para diagnosis y terapia de enfermedades asociadas con la expresion aberrante de futrinas (r-espondinas) y/o wnt.
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
DE102005035568A1 (de) 2005-07-25 2007-02-01 M-Phasys Gmbh Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
EP2044123B1 (en) 2006-06-21 2013-03-13 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to fzd10 and uses thereof
BRPI0713086A2 (pt) 2006-08-14 2012-10-09 Forerunner Pharma Res Co Ltd diagnóstico e tratamento de cáncer usando anticorpo anti-desmogleìna-3
US7982013B2 (en) 2008-09-26 2011-07-19 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
MX2011008044A (es) 2009-02-03 2012-01-12 Koninklijke Nederlandse Akademie Van Wetenschappen Medio de cultivo para celulas madre epiteliales y organoides que comprenden las celulas madre.
US9042340B2 (en) 2009-02-10 2015-05-26 Nokia Corporation Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment
EP2305274A1 (en) * 2009-09-21 2011-04-06 Centre National de la Recherche Scientifique (CNRS) Use of WNT stimulators for treating demyelinating diseases
CN102812047B (zh) 2009-12-09 2015-08-26 拜耳制药股份公司 抗C4.4a抗体及其用途
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
US10086043B2 (en) 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
WO2013071047A1 (en) 2011-11-11 2013-05-16 Children's Medical Center Corporation Compositions and methods for in vitro transcription of rna
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
BR112015002790A2 (pt) 2012-08-09 2017-08-08 Roche Glycart Ag anticorpos asgpr e usos dos mesmos.
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc Heterologous untranslated regions for mrna
CA2946308A1 (en) * 2014-04-21 2015-10-29 Abbvie Stemcentrx Llc Novel anti-rnf43 antibodies and methods of use
WO2016040895A1 (en) 2014-09-12 2016-03-17 xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Wnt signaling agonist molecules
AU2015340056A1 (en) 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
CN107250158B (zh) 2014-11-19 2022-03-25 基因泰克公司 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
EP3283068A1 (en) * 2015-04-17 2018-02-21 Merrimack Pharmaceuticals, Inc. Combination treatments with seribantumab
CA3002957A1 (en) * 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
US20190112588A1 (en) 2015-12-08 2019-04-18 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US20170349659A1 (en) 2016-06-03 2017-12-07 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
WO2018107116A1 (en) 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
AU2018211985B2 (en) 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
EP3619238A4 (en) 2017-05-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY INDUCING THERAPEUTIC
GB201708330D0 (en) 2017-05-24 2017-07-05 Koninklijke Nederlandse Akademie Van Wetenschappen Fusion protein for enhancing intestinal regeneration
US12006368B2 (en) 2017-12-19 2024-06-11 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
EP3731867A4 (en) 2017-12-19 2022-04-06 Surrozen Operating, Inc. Anti-lrp5/6 antibodies and methods of use
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
DK3820906T3 (da) 2018-07-05 2025-12-15 Surrozen Operating Inc Multispecifikke wnt-surrogatmolekyler og anvendelser deraf
CN112654363A (zh) 2018-07-09 2021-04-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
US20220064337A1 (en) 2018-12-19 2022-03-03 Surrozen, Inc. Antigen binding formats for receptor complexes
EP3924381A4 (en) 2019-02-11 2023-07-26 Surrozen Operating, Inc. MODULATION OF WNT SIGNALING IN EYE DISEASES
EP3938036A4 (en) 2019-03-11 2023-06-28 Surrozen Operating, Inc. Modulation of wnt signaling in gastrointestinal disorders
US20220175884A1 (en) 2019-04-02 2022-06-09 Surrozen Operating, Inc. Modulation of wnt signaling in auditory disorders
KR20220024460A (ko) 2019-06-11 2022-03-03 안틀라 테라퓨틱스 아이엔씨. 다가 fzd 및 wnt 결합 분자 및 이의 용도
US11050604B2 (en) 2019-07-01 2021-06-29 Rampart Communications, Inc. Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation
CN115427446A (zh) 2020-02-24 2022-12-02 瑟罗泽恩奥普瑞汀公司 Wnt超级激动剂
KR20230109668A (ko) 2020-11-16 2023-07-20 서로젠 오퍼레이팅, 인크. 간-특이적 Wnt 신호 증강 분자 및 그의 용도
US20240150473A1 (en) 2021-03-10 2024-05-09 Surrozen Operating, Inc. Modulation of wnt signaling in gastrointestinal disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008093646A1 (ja) 2007-02-01 2008-08-07 National University Corporation NARA Institute of Science and Technology Wntシグナル伝達系活性化ペプチド
JP2014530816A (ja) 2011-10-14 2014-11-20 ノバルティスアーゲー Ｗｎｔ経路関連疾患のための抗体および方法
JP2015511484A (ja) 2012-02-28 2015-04-20 ノバルティス アーゲー ＲＮＦ４３変異ステータスを利用したＷｎｔシグナル伝達阻害剤の投与のためのがん患者選択法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dominik Witzigmann，Hepatology Resarch，2016年，46(7)，686-696

Also Published As

Publication number Publication date
WO2018140821A1 (en) 2018-08-02
CA3050133A1 (en) 2018-08-02
EP3574019A4 (en) 2021-03-03
JP2023078467A (ja) 2023-06-06
AU2018211985A1 (en) 2019-07-18
EP3574019A1 (en) 2019-12-04
JP2025020347A (ja) 2025-02-12
CN110234662A (zh) 2019-09-13
JP2020506701A (ja) 2020-03-05
US11958891B2 (en) 2024-04-16
US20200048324A1 (en) 2020-02-13
US20240279303A1 (en) 2024-08-22
AU2018211985B2 (en) 2025-02-13
JP7635291B2 (ja) 2025-02-25

Similar Documents

Publication Publication Date Title
JP7635291B2 (ja) 組織特異的Ｗｎｔシグナル増強分子およびその使用
US12466884B2 (en) Tissue-specific WNT signal enhancing molecules and uses
JP7685737B2 (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
JP2023091081A (ja) Ｗｎｔシグナリングアゴニスト分子
CN112566940B (zh) 多特异性wnt替代分子和其用途
US12240876B2 (en) Liver-specific Wnt signal enhancing molecules and uses thereof
US20230399369A1 (en) Wnt signaling agonist molecules
JP2018515085A (ja) 抗がん融合ポリペプチド
JP2023515505A (ja) Ｗｎｔスーパーアゴニスト
JP2023543232A (ja) ヘッジホッグシグナル伝達経路の活性化のための強力な結合剤
CN116723867A (zh) 肝脏特异性Wnt信号增强分子及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190927

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230628

R150 Certificate of patent or registration of utility model

Ref document number: 7305543

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150